Posted: Friday, June 10, 2022
According to 3-year follow-up of outcomes from the ZUMA-2 trial, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7518), brexucabtagene autoleucel (KTE-X19) therapy resulted in long-term responses in patients with relapsed or refractory mantle cell lymphoma. Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues reported that the chimeric antigen receptor (CAR) T-cell therapy was associated “with manageable safety and low late relapse potential” in this patient population.
The study included 68 adults with relapsed or refractory mantle cell lymphoma who received one infusion of KTE-X19 following leukapheresis and conditioning chemotherapy. At a median follow-up of 35.6 months, the overall response rate was 91%. The complete response rate was 68%. The median duration of response was 28.2 months. Median progression-free survival was 25.8 months, and median overall survival was 46.6 months. A total of 29 patients were evaluated for measurable residual disease (MRD), 24 of whom were negative at 1 month; of the 19 patients with data available at 6 months, 15 achieved MRD negativity.
At the time of final data collection, 37% of patients (n = 25) were in ongoing complete response. Among the 15 patients who achieved MRD negativity at 6 months, the median duration of response, progression-free survival, and overall survival were not reached. In contrast, those durations for the four patients who remained MRD-positive at 4 months were 6.1 months, 7.1 months, and 27.0 months, respectively. An association was noted between MRD negativity at months 1, 3, and 6 and durable response. Circulating tumor DNA analysis at months 3 and 6 was predictive of relapse. The most commonly occurring adverse event of ≥ grade 3 was neutropenia. No new safety signals were noted during the study.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.